FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to the application of a coniferous provitamin concentrate, to a medication based on the coniferous provitamin concentrate, a pharmaceutical composition, containing the coniferous provitamin concentrate, and to a method of the prophylaxis and treatment of benign prostate hyperplasia.
EFFECT: coniferous provitamin concentrate possesses the rich composition of active substances, more expressed therapeutic and prophylactic effect with respect to benign prostate hyperplasia, as well as it has a better safety profile and a possibility of long-term application.
9 cl, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT PREVENTING PRECANCEROUS AND PROSTATE CANCER, PHARMACEUTICAL COMPOSITION, ACTIVE INGREDIENT OF PHARMACEUTICAL COMPOSITION AND METHOD FOR CHEMOPROPHYLAXIS OF PROSTATE CANCER | 2012 |
|
RU2585386C2 |
| METHOD FOR PREVENTING AND TREATING BENIGN PROSTATIC HYPERPLASIA | 2014 |
|
RU2574014C2 |
| METHOD AND REMEDY FOR TREATMENT AND PREVENTION OF BENIGN PROSTATIC HYPERPLASIA | 2019 |
|
RU2764850C1 |
| PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF PROSTATE PATHOLOGIES | 2017 |
|
RU2750992C2 |
| DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2011 |
|
RU2464574C1 |
| METHOD FOR PREDICTION OF RISK OF BIOCHEMICAL RECURRENT IN PROSTATE CANCER PATIENTS AFTER RADIATION AND HORMONE THERAPY | 2015 |
|
RU2605838C1 |
| REMEDY FOR THE PREVENTION AND TREATMENT OF PROSTATITIS AND BENIGN PROSTATE HYPERPLASIA | 2020 |
|
RU2751342C1 |
| MEANS AND METHOD OF CONDITIONS TREATMENT IMPLYING ANDROGEN ACTION DECREASE IS CONSIDERED TO BE FAVOURABLE, AND METHOD OF ANDROGEN-DEPENDENT TISSUE SENSITIVITY ITENSIFYING USING 9-OXOACRIDINE-10-ACETIC ACID | 2006 |
|
RU2328285C2 |
| ANTIPROLIFERATIVE AGENT | 2011 |
|
RU2519727C2 |
| MARKER OF PROSTATE GLAND CANCER | 2007 |
|
RU2360924C1 |
